NOTICE OF CONTRACT AWARD AND JUSTIFICATION & APPROVAL (J&A) POSTING

The Department of Defense’s Defense Health Agency, through its Contracting Division – Defense Healthcare Management Systems, has awarded contract HT003826FE006 on a sole-source basis to Leidos, Inc. under FAR 16.507-6(b)(2), citing the unique and highly specialized nature of the required services. This action supports pre-implementation, user adoption, change management, and cutover preparation for a “control” pilot of the Service Treatment Record Zero Day capability within the MHS GENESIS electronic health record system. The award is justified by Leidos’s decade-long, irreplaceable expertise in MHS GENESIS architecture, including deep familiarity with critical subsystems such as the Patient Identification Process and Revenue Cycle Expansion, as well as its established partnership with Oracle Health, the underlying platform. No competition was conducted, and the contract is not awarded under a lowest price technically acceptable approach. The estimated value is not to exceed $8,000,000, with a base period of performance lasting 180 days, beginning upon award and centered in Arlington, Virginia, at Defense Health Agency facilities. The contract serves as a benchmark for evaluating future data ecosystem innovations, with potential follow-on task orders contingent on the pilot’s success and broader government-wide scaling. The contract is issued under the GSA Alliant 2 indefinite-delivery, indefinite-quantity vehicle and involves no standard FAR 52-series clauses, as the document is strictly a post-award justification notice and not a fully executed contract. The scope includes delivering program management, technical documentation, stakeholder workshops, and data-driven outputs to ensure interoperability with federal partners such as the VA and Coast Guard, while maintaining compliance with federal statutes and DoD regulations. No line-item pricing, CLINs, or detailed cost breakdowns are provided; the $8 million represents the sole documented ceiling. Performance is subject to government inspection and acceptance, with the Defense Health Agency retaining oversight authority. No corporate representations, socioeconomic certifications, or security clearance requirements are specified, and no packaging, shipping, or marking standards apply, as the work is entirely service-based within the MHS GENESIS environment. The contracting officer, J. R. Oliver, certified the justification and approval, which was finalized on April 7, 2026, and publicly posted on May 8, 2026, with no opportunity for public response or further submissions.